期刊
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
卷 96, 期 -, 页码 182-193出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2017.10.008
关键词
Protein phosphatase 2A; PP2A; SET; CIP2A; PME-1; LCMT-1; FTY720; OP449; Bortezomib; Erlotinib; Celastrol; ABL-127; SMAPs; Phenothiazines; LB-100; Protein phosphatases; Drug development; Cancer; Cell signaling; Tumor suppressors
资金
- NCI NIH HHS [R01 CA181654, F31 CA213554] Funding Source: Medline
- NIGMS NIH HHS [T32 GM007250] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [F31CA213554, R01CA181654] Funding Source: NIH RePORTER
Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase that regulates many cellular processes. Given the central role of PP2A in regulating diverse biological functions and its dysregulation in many diseases, including cancer, PP2A directed therapeutics have become of great interest. The main approaches leveraged thus far can be categorized as follows: 1) inhibiting endogenous inhibitors of PP2A, 2) targeted disruption of post translational modifications on PP2A subunits, or 3) direct targeting of PP2A. Additional insight into the structural, molecular, and biological framework driving the efficacy of these therapeutic strategies will provide a foundation for the refinement and development of novel and clinically tractable PP2A targeted therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据